Technical Analysis for ANTH - Anthera Pharmaceutic
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Historical ANTH trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | -10.86% | |
Outside Day | Range Expansion | -10.86% | |
Wide Bands | Range Expansion | -10.86% | |
Lower Bollinger Band Touch | Weakness | -10.86% | |
Lower Bollinger Band Walk | Weakness | -12.73% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: California Biopharmaceutical Autoimmune Diseases Lisi Autoimmune Disease Pancreatic Eli Lilly And Company Amgen Mge Anthera Pharmaceuticals Enzyme Replacement Therapy Exocrine Pancreatic Insufficiency Hayward
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: California Biopharmaceutical Autoimmune Diseases Lisi Autoimmune Disease Pancreatic Eli Lilly And Company Amgen Mge Anthera Pharmaceuticals Enzyme Replacement Therapy Exocrine Pancreatic Insufficiency Hayward
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.189 |
52 Week Low | 0.01 |
Average Volume | 184,358 |
200-Day Moving Average | 0.0414 |
50-Day Moving Average | 0.0857 |
20-Day Moving Average | 0.0747 |
10-Day Moving Average | 0.0698 |
Average True Range | 0.0184 |
ADX | 17.03 |
+DI | 9.8761 |
-DI | 16.3052 |
Chandelier Exit (Long, 3 ATRs ) | 0.0438 |
Chandelier Exit (Short, 3 ATRs ) | 0.1067 |
Upper Bollinger Band | 0.0893 |
Lower Bollinger Band | 0.0601 |
Percent B (%b) | 0.08 |
BandWidth | 39.0897 |
MACD Line | -0.0044 |
MACD Signal Line | -0.0038 |
MACD Histogram | -0.0006 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.0842 | ||||
Resistance 3 (R3) | 0.0843 | 0.0771 | 0.0805 | ||
Resistance 2 (R2) | 0.0771 | 0.0716 | 0.0771 | 0.0793 | |
Resistance 1 (R1) | 0.0698 | 0.0682 | 0.0662 | 0.0697 | 0.0781 |
Pivot Point | 0.0626 | 0.0626 | 0.0609 | 0.0626 | 0.0626 |
Support 1 (S1) | 0.0553 | 0.0571 | 0.0517 | 0.0552 | 0.0467 |
Support 2 (S2) | 0.0481 | 0.0537 | 0.0481 | 0.0455 | |
Support 3 (S3) | 0.0408 | 0.0481 | 0.0443 | ||
Support 4 (S4) | 0.0407 |